Results
In-person events
Out-of-Office Live
Speaker:
Katie Murray, DO, MS, FACS
Fushimi Times Square, 311 W 43rd Street, New York, NY 10036
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Dana Moore, MBA, MPH
Revere Hotel Boston Common, 425 Summer Street, Boston, MA 02210
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Aaron Berger, MD
AUI Ocala: Oxford (LUA) (Care Center 4), 12109 CR 103, Oxford, FL 34484
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Katie Murray, DO, MS, FACS
The Shipwright's Daughter, 210 E Main Street, Mystic, CT 06355
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Katie Murray, DO, MS, FACS
The Banks Seafood and Steak, 406 Stuart Street, Boston, MA 02116
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Stephanie Strobl, APRN
The Westin Boston Seaport District, 425 Summer Street, Boston, MA 02210
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Lawrence Karsh, MD, FACS, CPI
Trulucks, 10225 Research Blvd, Austin, TX 78759
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Ravi Chauhan, MD
Del Frisco's Grille, 5061 Westheimer Road, Houston, TX 77056
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Aaron Berger, MD
Hilton BNA Nashville Airport, 2 Terminal Drive, Nashville, TN 37214
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
In-Office Live
Speaker:
Lawrence Karsh, MD, FACS, CPI
Arkansas Urology, 1300 Centerview Drive, Little Rock, AR 72211
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Katie Murray, DO, MS, FACS
Black and Blue, 1470 Western Ave, Albany, NY 12203
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Lambros Stamatakis, MD
Cedar Creek Grille, 2101 Richmond Road, Beachwood, OH 44122
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Ravi Chauhan, MD
Forbes Mill Steakhouse, 200 Sycamore Valley Rd W, Danville, CA 94526
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.